Company news

Cardiol Therapeutics Inc. news in 2025

Cardiol Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

December 1, 2025

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

November 13, 2025

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

November 5, 2025

Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027

October 21, 2025

Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027

October 17, 2025

Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

August 11, 2025

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

August 6, 2025

Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis

July 22, 2025

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders

May 29, 2025

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4: 30 p.m. EDT

May 27, 2025

Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors

April 29, 2025

Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

April 16, 2025

Cardiol Therapeutics Announces Year-End 2024 Update on Operations

April 1, 2025

Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

March 3, 2025

Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure

February 20, 2025

Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025

Decks in 2025